|
Monday, 08/02/2010
|
Simulation of Kidney Paired Donation Programs
Yijiang (John) Li, University of Michigan; Yan Zhou, University of Michigan; John David Kalbfleisch, University of Michigan; Peter Song, University of Michigan
|
Statistical Reasons Why Preference-Scored Measures of HRQoL Disagree
Mari Palta, University of Wisconsin
|
Futility Assessment Utilizing Conditional Power in a Phase III Clinical Trial
Yan Sun, Amgen Inc.
8:35 AM
|
Sample Size and Power Considerations for Futility Trial Design: Buying Power vs. Spending Beta
Thomas Dobbins, Merck & Co., Inc.
8:50 AM
|
Bayesian Decision Analysis for Diagnostic Procedures
Ying Lu, Stanford University; John Kornak, University of California, San Francisco
9:35 AM
|
Should the Conditional Type I Error Be Controlled?
Tie-Hua Ng, FDA
9:50 AM
|
Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
Myron N. Chang, University of Florida; Sin-Ho Jung, Duke University
10:05 AM
|
|
Thursday, 08/05/2010
|
Risk Models for Deciding Whether to Take Tamoxifen to Prevent Breast Cancer and for Allocating Public Health Resources
Mitchell H. Gail, National Cancer Institute
8:35 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
Analysis of Discrete Choice Models with Latent Variable in Unobserved Component of Utility
Woosuk Kim, University of Cincinnati; Seongho Song, University of Cincinnati; Young Seuk Cho, Pusan National University
11:05 AM
|
|